Pharmaceutical Executive

Pharmaceutical Executive: October 2026
Volume: 46
Issue: 8

Pharmaceutical Executive: September 2026
Volume: 46
Issue: 7
Pharmaceutical Executive: August 2026
Volume: 46
Issue: 6

Pharmaceutical Executive: June 2026
Volume: 46
Issue: 5

Pharmaceutical Executive: May 2026
Volume: 46
Issue: 4

Pharmaceutical Executive: April 2026
Volume: 46
Issue: 3

Pharmaceutical Executive: March 2026
Volume: 46
Issue: 2

Pharmaceutical Executive: February 2026
Volume: 46
Issue: 1

Pharmaceutical Executive: December 2025
Volume: 45
Issue: 9

Pharmaceutical Executive: October 2025
Volume: 45
Issue: 8

Pharmaceutical Executive: September 2025
Volume: 45
Issue: 7

Pharmaceutical Executive: August 2025
Volume: 45
Issue: 6

Pharmaceutical Executive: June 2025
Volume: 45
Issue: 5

Pharmaceutical Executive: May 2025
Volume: 45
Issue: 4

Pharmaceutical Executive: April 2025
Volume: 45
Issue: 3

Pharmaceutical Executive: March 2025
Volume: 45
Issue: 2

Pharmaceutical Executive: February 2025
Volume: 45
Issue: 1

Pharmaceutical Executive: December 2024
Volume: 44
Issue: 12

Pharmaceutical Executive: November 2024
Volume: 44
Issue: 11

Pharmaceutical Executive: October 2024
Volume: 44
Issue: 10

Pharmaceutical Executive: September 2024
Volume: 44
Issue: 9

Pharmaceutical Executive: July/August 2024
Volume: 44
Issue: 7/8

Pharmaceutical Executive: June 2024
Volume: 44
Issue: 6

Pharmaceutical Executive: May 2024
Volume: 44
Issue: 5

Pharmaceutical Executive: April 2024
Volume: 44
Issue: 4

Pharmaceutical Executive: March 2024
Volume: 44
Issue: 3

Pharmaceutical Executive: February 2024
Volume: 44
Issue: 1

Pharmaceutical Executive: December 2023
Volume: 43
Issue: 12

Pharmaceutical Executive: November 2023
Volume: 43
Issue: 11

Pharmaceutical Executive: October 2023
Volume: 43
Issue: 10
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD Therpaeutics Acquires AD04 Alzheimers Program, Sanofi Enters Collaboration with Seawolf Therapeutics
2
The Hidden Risk in Pharma’s AI Rush
3
FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia
4
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
5
